D. E. Shaw & Co., Inc. Immatics N.V. Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Immatics N.V. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 63,647 shares of IMTX stock, worth $519,995. This represents 0.0% of its overall portfolio holdings.
Number of Shares
63,647Holding current value
$519,995% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IMTX
# of Institutions
101Shares Held
75.8MCall Options Held
238KPut Options Held
727K-
Rtw Investments, LP New York, NY10MShares$81.7 Million1.82% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$79.1 Million0.02% of portfolio
-
Perceptive Advisors LLC New York, NY8.09MShares$66.1 Million2.41% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD7.38MShares$60.3 Million0.05% of portfolio
-
Baker Bros. Advisors LP New York, NY6.44MShares$52.6 Million0.79% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $623M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...